Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
treatment
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
26 mars 2025 15h00 HE
|
Custom Market Insights
Austin, TX, USA, March 27, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme...
[Latest] Global Medical Radioisotopes Market Size/Share Worth USD 1382 Million by 2034 at a 6.34% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
20 mars 2025 04h30 HE
|
Custom Market Insights
Austin, TX, USA, March 20, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Radioisotopes Market Size, Trends and Insights By Type (Tc-99m,...
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
18 mars 2025 09h30 HE
|
Biofrontera Inc.
First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of...
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy
18 mars 2025 08h46 HE
|
Today's Marketplace
Today's Marketplace interview about epilepsy treatment with NeuroOne CEO and Creighton University
Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions
12 mars 2025 09h30 HE
|
BIOXYTRAN, INC.
New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks BOSTON, MASSACHUSETTS, March 12, 2025 (GLOBE NEWSWIRE) --...
Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer
29 janv. 2025 10h19 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY
28 janv. 2025 08h05 HE
|
FOXO Technologies Inc.
MINNEAPOLIS, MN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), provides a brief shareholder letter from Seamus Lagan, recently appointed CEO of FOXO...
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
27 janv. 2025 07h00 HE
|
GT Biopharma, Inc.
Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology...
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
22 janv. 2025 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
08 janv. 2025 09h50 HE
|
Biofrontera Inc.
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically...